MA51988A - Procédé pour la préparation de composés utiles à traiter l'amyotrophie spinale - Google Patents
Procédé pour la préparation de composés utiles à traiter l'amyotrophie spinaleInfo
- Publication number
- MA51988A MA51988A MA051988A MA51988A MA51988A MA 51988 A MA51988 A MA 51988A MA 051988 A MA051988 A MA 051988A MA 51988 A MA51988 A MA 51988A MA 51988 A MA51988 A MA 51988A
- Authority
- MA
- Morocco
- Prior art keywords
- preparation
- compounds useful
- treating spinal
- spinal amyotrophy
- amyotrophy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461993839P | 2014-05-15 | 2014-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51988A true MA51988A (fr) | 2021-01-20 |
Family
ID=53175048
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39995A MA39995B1 (fr) | 2014-05-15 | 2015-05-11 | Composés destinés à traiter l'amyotrophie spinale |
| MA051988A MA51988A (fr) | 2014-05-15 | 2015-05-11 | Procédé pour la préparation de composés utiles à traiter l'amyotrophie spinale |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39995A MA39995B1 (fr) | 2014-05-15 | 2015-05-11 | Composés destinés à traiter l'amyotrophie spinale |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US9969754B2 (fr) |
| EP (3) | EP3663296B1 (fr) |
| JP (1) | JP6236173B2 (fr) |
| KR (2) | KR102213740B1 (fr) |
| CN (1) | CN106459092B (fr) |
| AR (1) | AR100442A1 (fr) |
| AU (1) | AU2015261046C1 (fr) |
| BR (1) | BR112016026205B1 (fr) |
| CA (1) | CA2948561C (fr) |
| CL (1) | CL2016002836A1 (fr) |
| CR (1) | CR20160518A (fr) |
| DK (1) | DK3143025T3 (fr) |
| EA (2) | EA202090486A3 (fr) |
| ES (2) | ES2761423T3 (fr) |
| FR (1) | FR21C1039I2 (fr) |
| HR (2) | HRP20230637T1 (fr) |
| HU (2) | HUE046491T2 (fr) |
| IL (2) | IL248653B (fr) |
| LT (1) | LTPA2021010I1 (fr) |
| MA (2) | MA39995B1 (fr) |
| MX (1) | MX371050B (fr) |
| MY (1) | MY174284A (fr) |
| NL (1) | NL301128I2 (fr) |
| NO (1) | NO2021035I1 (fr) |
| NZ (1) | NZ725008A (fr) |
| PE (1) | PE20170128A1 (fr) |
| PH (1) | PH12016502081A1 (fr) |
| PL (2) | PL3143025T3 (fr) |
| PT (1) | PT3143025T (fr) |
| RS (1) | RS59718B1 (fr) |
| SG (1) | SG11201609497TA (fr) |
| SI (2) | SI3143025T1 (fr) |
| TW (1) | TWI667239B (fr) |
| UA (1) | UA119670C2 (fr) |
| WO (1) | WO2015173181A1 (fr) |
| ZA (1) | ZA201607026B (fr) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2697174T3 (es) | 2012-02-10 | 2019-01-22 | Ptc Therapeutics Inc | Compuestos para tratar atrofia muscular espinal |
| EP3035935B1 (fr) | 2013-08-19 | 2020-03-11 | F. Hoffmann-La Roche AG | Composés utiles dans la prévention et le traitement du cancer |
| US10882868B2 (en) * | 2014-05-15 | 2021-01-05 | Hoffmann-La Roche Inc. | Compounds for treating spinal muscular atrophy |
| WO2016184832A1 (fr) | 2015-05-20 | 2016-11-24 | F. Hoffmann-La Roche Ag | Composés pour le traitement d'une amyotrophie spinale |
| WO2016196386A1 (fr) | 2015-05-30 | 2016-12-08 | Ptc Therapeutics, Inc. | Procédés de modulation de l'épissage de l'arn |
| AU2016353961B2 (en) * | 2015-11-12 | 2019-08-29 | F. Hoffmann-La Roche Ag | Compositions for treating spinal muscular atrophy |
| JP2018533594A (ja) * | 2015-11-12 | 2018-11-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 筋萎縮性側索硬化症を処置するための化合物 |
| DK3386511T3 (da) | 2015-12-10 | 2021-07-05 | Ptc Therapeutics Inc | Fremgangsmåder til behandling af huntingtons sygdom |
| JP6872550B2 (ja) | 2015-12-10 | 2021-05-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 架橋されたピペリジン誘導体 |
| JP2019535789A (ja) * | 2016-11-28 | 2019-12-12 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｒｎａスプライシングを調節する方法 |
| EP3634953B1 (fr) | 2017-06-05 | 2024-01-03 | PTC Therapeutics, Inc. | Composés permettant de traiter la maladie de huntington |
| EA202090034A1 (ru) | 2017-06-14 | 2020-04-16 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы модификации сплайсинга рнк |
| WO2019005980A1 (fr) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Procédés de traitement de la maladie de huntington |
| EP3645121A4 (fr) | 2017-06-28 | 2021-03-17 | PTC Therapeutics, Inc. | Méthodes de traitement de la maladie de huntington |
| CN116813648A (zh) * | 2017-09-22 | 2023-09-29 | 豪夫迈·罗氏有限公司 | 制备2-(2,8-二甲基咪唑并[1,2-b]哒嗪-6-基)吡啶并[1,2-a]嘧啶-4-酮衍生物的方法 |
| CA3078137A1 (fr) * | 2017-10-03 | 2019-04-11 | F. Hoffmann-La Roche Ag | Nouveau traitement de la sma |
| BR112020019373A2 (pt) | 2018-03-27 | 2020-12-29 | Ptc Therapeutics, Inc. | Compostos para o tratamento da doença de hutington |
| US11685746B2 (en) | 2018-06-27 | 2023-06-27 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
| AU2019294478B2 (en) | 2018-06-27 | 2023-03-23 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating Huntington's disease |
| MX2020014116A (es) | 2018-06-27 | 2021-06-15 | Reborna Biosciences Inc | Agente profilactico o terapeutico para atrofia muscular espinal. |
| TW202035411A (zh) | 2018-10-19 | 2020-10-01 | 瑞士商赫孚孟拉羅股份公司 | 吡啶并[1,2-a]嘧啶-4-酮衍生物之新型式、及調配物及製備方法 |
| JP2022536669A (ja) | 2019-06-12 | 2022-08-18 | エフ．ホフマン－ラ ロシュ アーゲー | Ｓｍａの新規治療 |
| EP4004003A1 (fr) | 2019-07-31 | 2022-06-01 | Teva Pharmaceuticals International GmbH | Formes à l'état solide de risdiplam et leurs procédés de préparation |
| WO2022048675A1 (fr) * | 2020-09-07 | 2022-03-10 | 苏州科睿思制药有限公司 | Forme cristalline du risdiplam, son procédé de préparation et son utilisation |
| WO2022162107A1 (fr) | 2021-02-01 | 2022-08-04 | Sandoz Ag | Forme cristalline de risdiplam |
| JP2024510487A (ja) * | 2021-03-17 | 2024-03-07 | エフ． ホフマン－ラ ロシュ アーゲー | 新規なチアジアゾロピリミドン誘導体 |
| AU2022240935A1 (en) | 2021-03-17 | 2023-08-24 | F. Hoffmann-La Roche Ag | New thiazolopyrimidinone derivatives |
| JP2024509995A (ja) | 2021-03-18 | 2024-03-05 | エフ． ホフマン－ラ ロシュ アーゲー | リスジプラムを調製するための方法 |
| EP4426306A1 (fr) | 2021-10-06 | 2024-09-11 | F. Hoffmann-La Roche AG | Nouvelle administration combinée |
| CN118005654A (zh) * | 2022-04-18 | 2024-05-10 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡啶并嘧啶酮类化合物及包含该化合物的组合物及其用途 |
| WO2023240236A1 (fr) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions et procédés pour le traitement de troubles liés à l'amyotrophie spinale |
| WO2024069646A1 (fr) * | 2022-09-26 | 2024-04-04 | Natco Pharma Limited | Procédé amélioré pour la préparation de risdiplam et de ses intermédiaires |
| WO2024081932A1 (fr) | 2022-10-14 | 2024-04-18 | Genentech, Inc. | Méthodes de traitement de l'amyotrophie spinale |
| WO2024154148A1 (fr) * | 2023-01-21 | 2024-07-25 | Harman Finochem Limited | Procédé de préparation de risdiplatine, nouveaux intermédiaires et leur procédé de préparation |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0920429T3 (da) * | 1996-08-06 | 2003-05-12 | Pfizer | Substituerede pyrido- eller pyrimidoholdige, 6,6- eller 6,7-bicykliske derivater |
| AU2008304231A1 (en) | 2007-09-27 | 2009-04-02 | Albany Molecular Research, Inc. | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| US8633019B2 (en) * | 2008-05-27 | 2014-01-21 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| KR20100012134A (ko) * | 2008-07-28 | 2010-02-08 | 신호열 | 마우스 |
| WO2010019236A1 (fr) | 2008-08-13 | 2010-02-18 | Ptc Therapeutics, Inc | Méthodes de traitement de l’atrophie musculaire spinale |
| WO2010019326A1 (fr) * | 2008-08-14 | 2010-02-18 | Cardiac Pacemakers, Inc. | Évaluation et adaptation des performances d’une liaison de communication acoustique |
| JP6193881B2 (ja) * | 2011-12-30 | 2017-09-06 | ピーティーシー セラピューティクス， インコーポレイテッド | 脊髄性筋萎縮症を治療するための化合物 |
| ES2697174T3 (es) | 2012-02-10 | 2019-01-22 | Ptc Therapeutics Inc | Compuestos para tratar atrofia muscular espinal |
| US9212209B2 (en) | 2012-07-13 | 2015-12-15 | Indiana University Research And Technology Corporation | Screening methods for spinal muscular atrophy |
| AU2016353961B2 (en) | 2015-11-12 | 2019-08-29 | F. Hoffmann-La Roche Ag | Compositions for treating spinal muscular atrophy |
-
2015
- 2015-05-11 PT PT157217019T patent/PT3143025T/pt unknown
- 2015-05-11 MA MA39995A patent/MA39995B1/fr unknown
- 2015-05-11 HR HRP20230637TT patent/HRP20230637T1/hr unknown
- 2015-05-11 EA EA202090486A patent/EA202090486A3/ru unknown
- 2015-05-11 RS RS20191541A patent/RS59718B1/sr unknown
- 2015-05-11 SG SG11201609497TA patent/SG11201609497TA/en unknown
- 2015-05-11 KR KR1020167034983A patent/KR102213740B1/ko active IP Right Grant
- 2015-05-11 CN CN201580027306.9A patent/CN106459092B/zh active Active
- 2015-05-11 WO PCT/EP2015/060343 patent/WO2015173181A1/fr active Application Filing
- 2015-05-11 AU AU2015261046A patent/AU2015261046C1/en active Active
- 2015-05-11 PL PL15721701T patent/PL3143025T3/pl unknown
- 2015-05-11 KR KR1020217002966A patent/KR102256013B1/ko active IP Right Grant
- 2015-05-11 MA MA051988A patent/MA51988A/fr unknown
- 2015-05-11 PE PE2016002128A patent/PE20170128A1/es unknown
- 2015-05-11 UA UAA201612716A patent/UA119670C2/uk unknown
- 2015-05-11 CR CR20160518A patent/CR20160518A/es unknown
- 2015-05-11 EP EP19200058.6A patent/EP3663296B1/fr active Active
- 2015-05-11 JP JP2016567816A patent/JP6236173B2/ja active Active
- 2015-05-11 SI SI201531021T patent/SI3143025T1/sl unknown
- 2015-05-11 EP EP23169721.0A patent/EP4241772A3/fr active Pending
- 2015-05-11 HU HUE15721701A patent/HUE046491T2/hu unknown
- 2015-05-11 ES ES15721701T patent/ES2761423T3/es active Active
- 2015-05-11 DK DK15721701T patent/DK3143025T3/da active
- 2015-05-11 EP EP15721701.9A patent/EP3143025B1/fr active Active
- 2015-05-11 ES ES19200058T patent/ES2949660T3/es active Active
- 2015-05-11 EA EA201692280A patent/EA035068B1/ru active Protection Beyond IP Right Term
- 2015-05-11 CA CA2948561A patent/CA2948561C/fr active Active
- 2015-05-11 PL PL19200058.6T patent/PL3663296T3/pl unknown
- 2015-05-11 MX MX2016014547A patent/MX371050B/es active IP Right Grant
- 2015-05-11 SI SI201531952T patent/SI3663296T1/sl unknown
- 2015-05-11 BR BR112016026205-0A patent/BR112016026205B1/pt active IP Right Grant
- 2015-05-11 MY MYPI2016001903A patent/MY174284A/en unknown
- 2015-05-11 NZ NZ72500815A patent/NZ725008A/en unknown
- 2015-05-14 TW TW104115433A patent/TWI667239B/zh active
- 2015-05-14 AR ARP150101500A patent/AR100442A1/es not_active Application Discontinuation
-
2016
- 2016-10-12 ZA ZA2016/07026A patent/ZA201607026B/en unknown
- 2016-10-19 PH PH12016502081A patent/PH12016502081A1/en unknown
- 2016-10-31 IL IL24865316A patent/IL248653B/en active IP Right Grant
- 2016-11-08 CL CL2016002836A patent/CL2016002836A1/es unknown
- 2016-11-14 US US15/351,267 patent/US9969754B2/en active Active
-
2019
- 2019-10-17 IL IL270027A patent/IL270027B/en active IP Right Grant
- 2019-11-29 HR HRP20192159TT patent/HRP20192159T1/hr unknown
-
2021
- 2021-09-09 FR FR21C1039C patent/FR21C1039I2/fr active Active
- 2021-09-10 NO NO2021035C patent/NO2021035I1/no unknown
- 2021-09-14 HU HUS2100037C patent/HUS2100037I1/hu unknown
- 2021-09-14 LT LTPA2021010C patent/LTPA2021010I1/lt unknown
- 2021-09-15 NL NL301128C patent/NL301128I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51988A (fr) | Procédé pour la préparation de composés utiles à traiter l'amyotrophie spinale | |
| MA44083A (fr) | Composés de biarylmonobactame pour le traitement d'infections bactériennes | |
| MA52665A (fr) | Procédé d'amélioration de l'expression de l'hémoglobine foetale | |
| MA43872A (fr) | Procédé de traitement d'une glomérulopathie à c3 | |
| MA54253A (fr) | Procédé de préparation de dérivés de 2-chloro-4-hétéroaryl-pyridimidines | |
| MA41200B1 (fr) | Procédé pour la préparation d'un composé diarylthiohydantoïne | |
| MA49752A (fr) | Procédés de préparation de composés de pyrrolidine | |
| MA52906A (fr) | Procédé de préparation d'amg 416 | |
| MA43099A (fr) | Procédé pour la préparation de chlorure de vinyle | |
| MA42953A (fr) | Composés et compositions pour le traitement de troubles oculaires | |
| MA55917A (fr) | Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie | |
| MA50169A (fr) | Procédé de production d'un électrocatalyseur | |
| MA42423A (fr) | Procédé de préparation d'un revêtement | |
| ES2837136R1 (es) | Proceso para la preparación de 3alfa-hidroxi-5alfa-pregnan-20-ona (Brexanolona) | |
| MA51738A (fr) | Composés pour le traitement de la douleur | |
| IL259297A (en) | Heterocyclic compounds for the treatment of disease | |
| MA49700A (fr) | Procédé amélioré pour la préparation de dérivés d'aminopyrimidine | |
| FR3038312B1 (fr) | Procede de preparation de polyols | |
| FR3050460B1 (fr) | Procede d'obtention d'une substance minerale cimentaire | |
| MA45768A (fr) | Procédé pour la préparation de compositions d'immunoglobulines | |
| MA51870A (fr) | Procédé pour la préparation de composés coupleurs de médicaments | |
| FR3048968B1 (fr) | Procede de preparation d'alkylamines | |
| PL3285755T3 (pl) | Chlorowodorek kreatyny do leczenia choroby Huntingtona | |
| MA51339A (fr) | Procédé de préparation de composés pyrimidinyl-4-aminopyrazole | |
| MA42264A (fr) | Procédé de préparation d'oltipraz |